/cdn.vox-cdn.com/uploads/chorus_image/image/64838968/usa_today_12831556.0.jpg)
Wide receiver Golden Tate signed with the Giants this offseason — after just half a year in Philly — and seems to be the latest domino to fall within New York’s offense.
Tate is facing a four-game suspension for violating the NFL’s performance enhancing drug policy, which exacerbates news this week that Sterling Shepard could miss time with a broken finger and Corey Coleman is out for the season with a torn ACL — both injuries suffered during the team’s first two training camp practices.
Tate plans to appeal the suspension, and will state his case the first week in August. NFL insider Adam Schefter is reporting that the decision should come down before the regular season. And while he may have a strong case, the league hasn’t often shown leniency with this particular rule.
My statement. pic.twitter.com/WzP7W4bclB
— Golden Tate (@ShowtimeTate) July 27, 2019
Giants GM Dave Gettleman announced that the team will be bringing in free agents for workouts to try and fill some depth at wide receiver (including Kelvin Benjamin, which, okay...), but the depth chart looks not so great.
Aside from Shepard, Coleman and Tate, fifth-round rookie receiver Darius Slayton is also dealing with a hamstring injury, leaving Cody Latimer and Bennie Fowler as the healthy options.
Eli Manning could face a lot less criticism this season if he doesn’t have any targets to try and avoid overthrowing — but that also means another grueling workload for Saquon Barkley.